uPARCRPC: Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer

Sponsor

Kristoffer Staal Rohrberg (Other)

Overall Status

Terminated

CT.gov ID

NCT02125617

Collaborator

Janssen-Cilag Ltd. (Industry)

Enrollment

Location

Duration (Months)

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate cleavage products of the urokinase plasminogenactivator receptor (uPAR) in plasma from patients with castration resistant prostate cancer as a predictive marker of response to abiraterone.

Condition or Disease	Intervention/Treatment	Phase
Prostatic Neoplasms	Drug: Abiraterone Drug: Prednisolone

Study Design

Study Type:

Observational

Actual Enrollment :

3 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

uPAR in Blood From Zytiga® (Abiraterone) Treated Patients With Castration Resistant Prostate Cancer - a Predictive Marker of Response?

Study Start Date :

Jan 1, 2014

Anticipated Primary Completion Date :

Jul 1, 2016

Anticipated Study Completion Date :

Feb 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Castration-resistant prostate cancer, Progression after taxane Treated with abiraterone 1000 mg/day Prednisolone 10 mg/day	Drug: Abiraterone 1000 mg/day Other Names: Zytiga® Drug: Prednisolone 10 mg/day

Arm

Intervention/Treatment

Castration-resistant prostate cancer, Progression after taxane

Treated with abiraterone 1000 mg/day Prednisolone 10 mg/day

Drug: Abiraterone

1000 mg/day

Other Names:

Zytiga®

Drug: Prednisolone

10 mg/day

Outcome Measures

Primary Outcome Measures

Impact of baseline uPAR cleavage products on response. [6 months]
Impact of baseline plasma concentration of uPAR cleavage products on overall response rate (ORR) defined as the proportion of patients with radiologic response according to the RECIST criteria or PSA-response.

Secondary Outcome Measures

Impact of baseline plasma concentration of uPAR cleavage products on overall survival (OS). [6 months]
Impact of baseline plasma concentration of uPAR cleavage products on overall survival (OS).
Impact of baseline plasma concentration of uPAR cleavage products on progression free survival (PFS). [6 months]
Impact of baseline plasma concentration of uPAR cleavage products on progression free survival (PFS).
Impact of baseline plasma concentration of uPAR cleavage products on pain relief rate. [6 months]
Impact of baseline plasma concentration of uPAR cleavage products on pain relief rate.
Impact of baseline plasma concentration of uPAR cleavage products on disease control rate (DCR). [6 months]
Impact of baseline plasma concentration of uPAR cleavage products on disease control rate (DCR).
Impact of baseline plasma concentration of uPAR cleavage products on serious adverse events (SAE). [6 months]
Impact of baseline plasma concentration of uPAR cleavage products on serious adverse events (SAE).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 120 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

Signed informed consent.
Age ≥18 years and male
Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
Received at least one but not more than two cytotoxic chemotherapy regimens for metastatic CRPC. At least one regimen must have contained a taxane such as docetaxel.
Prostate cancer progression as assessed by the investigator with one of the following:
PSA progression according to Prostate Cancer Working Group 2 (PCWG2) criteria
Solid Tumors (RECIST) criteria or bone scans with or without PSA progression.
Radiographic progression in soft tissue according to Response Evaluation Criteria in
Ongoing androgen deprivation with serum testosterone <2.0 nM
Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
Platelet count ≥100,000/μL
Serum albumin ≥30 g/dL
Serum creatinine <1.5 x upper limit of normal (ULN) or a calculated creatinine clearance ≥ 60 mL/min
Serum potassium ≥3.5 mmol/L

Exclusion Criteria:

Received abiraterone or MDV3100 in the past.
Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection.
Abnormal liver functions consisting of any of the following:
Serum bilirubin ≥1.5 x ULN (except for subjects with documented Gilbert's disease, for whom the upper limit of serum bilirubin is 51 µmol/l)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5 x ULN
Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg); subjects with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy.
Active or symptomatic viral hepatitis or chronic liver disease
History of pituitary or adrenal dysfunction
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or left ventricular ejection fraction (LVEF) of <50% at baseline.
Known brain metastasis
History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study drug
Any acute toxicities due to prior chemotherapy or radiotherapy that have not resolved to a NCI-CTCAE (Version 4.0) Grade of ≤1. Chemotherapy induced alopecia and Grade 2 peripheral neuropathy is allowed.
Use of other anticancer therapy including cytotoxic, radionucleotide, and immunotherapy; diethylstilbestrol; PC-SPES; spironolactone (ie, ALDACTONE, SPIRONOL); and other preparations such as saw palmetto thought to have endocrine effects on prostate cancer, within 4 weeks of Cycle 1 Day 1
Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole, ketoconazole) within 4 weeks of Cycle 1 Day 1
Current enrolment in an investigational drug or device study or participation in such a study within 30 days of Day 1
Condition or situation which, in the investigator's opinion, may put the subjects at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study.